Crossmark

Current childhood chronic myeloid leukemia management under tyrosine kinase inhibitor treatment

Crossref DOI link: https://doi.org/10.1007/s12185-022-03497-4

Published Online: 2022-11-19

Published Print: 2023-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Karadaş, Nihal https://orcid.org/0000-0002-0019-7347
Göktepe, Şerife Şebnem Önen https://orcid.org/0000-0002-6772-237X
Baş, İlke https://orcid.org/0000-0002-2849-5215
Ece, Dilek https://orcid.org/0000-0002-8003-3106
Özdemir, Hamiyet Hekimci https://orcid.org/0000-0001-8347-1817
Balkan, Can https://orcid.org/0000-0002-6244-9765
Kavaklı, Kaan https://orcid.org/0000-0003-1174-1958
Aydinok, Yeşim https://orcid.org/0000-0001-6194-6826
Karapinar, Deniz Yilmaz https://orcid.org/0000-0002-1637-4678
License Information

Text and Data Mining valid from 2022-11-19

Version of Record valid from 2022-11-19
More Information

Article History

Received: 11 April 2022

Revised: 14 November 2022

Accepted: 14 November 2022

First Online: 19 November 2022

Declarations

:

: The authors declare that they have no conflict of interest.